The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
GCLLSG 2016 | An overview of iwCLL 2017 meeting in New York by Prof. Michael Hallek
Michael Hallek, MD, PhD of the University of Cologne, Cologne, Germany discusses the iwCLL 2017 meeting to be held in New York in May 2017 (http://www.iwcll2017.org/). Prof. Hallek explains that the meeting will cover all aspects of biology and treatment in chronic lymphocytic leukemia (CLL). He believes that as more mature data will be available next year on novel drugs, they will be a main focus of discussion at the meeting. There will also be a young investigator meeting and Prof. Hallek is expecting many young investigators who will present their latest data. Another focus of the meeting will be on the genomic data and the question of how this data will have a clinical impact.
Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) held in Cologne, Germany.
